HUTCHMED

Hong Kong, Shanghai and Florham Park, NJ — Tuesday, July 6, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) has initiated a Phase I study of HMPL‑295, its investigative and highly selective oral inhibitor of ERK, which

Monthly Return

Total Voting Rights

HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy

HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting

Monthly Return

HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma

Total Voting Rights

HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China

Grant of Awards under Long Term Incentive Plan

Monthly Return

Total Voting Rights

HUTCHMED Highlights Oral Presentations at 2021 Chinese Society of Clinical Oncology Annual Meeting

HUTCHMED Announces Closing of Divestment of Non-Core OTC Joint Venture

HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with TUOYI® in the Treatment of Advanced Neuroendocrine Carcinoma in China

HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors

HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma

HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference

HUTCHMED Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs

Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan

Monthly Return

Total Voting Rights

HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer

HUTCHMED Selected as Constituent of Certain Hang Seng Indexes

Electronic Communication of Corporate Information

Election of language and means of receipt of corporate communications

HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China

Monthly Return

Total Voting Rights

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

HUTCHMED Reports 2021 Interim Results and Provides Business Updates

HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer

Stabilizing Actions and End of Stabilization Period in connection with the Global Offering

TR-1: Standard form for notification of major holdings

HUTCHMED’s Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency

TR-1: Standard form for notification of major holdings

First Commercial Sale of ORPATHYS® in China Triggering a US$25 million Milestone Payment from AstraZeneca

HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering

Monthly Return

HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL-295 in Patients with Advanced Solid Tumors in China

TR-1: Standard form for notification of major holdings

HUTCHMED to Announce 2021 Half-Year Financial Results

U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

Total Voting Rights

Holdings in Company

HUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong Kong

Blocklisting Six Monthly Return

List of Directors and Their Roles and Functions

ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS

HUTCHMED Announces Pricing of Global Offering